NICE
NICE tells pharma: don’t blame us for rejections
November 18, 2013Sales and Marketing Dillon, NHS, NICE, VBP
The head of NICE has publicly defended his agency against more pharma criticism but admits that it can make changes …
NICE needs more Velcade data
November 12, 2013Sales and Marketing NHS, NICE, Velcade, eric low
NICE has slowed the progress of Janssen Cilag’s Velcade towards becoming an NHS treatment for multiple myeloma by asking the …
The CDF: friend and foe?
November 11, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, CDF, Cancer, NICE, eric low
Few things in my professional life have troubled me more than the Cancer Drugs Fund (CDF) since its inception in …
NICE ‘yes’ to Lucentis – with price cut
October 25, 2013Sales and Marketing Dillon, Lucentis, NICE, Novartis
A price cut is the deal-breaking condition attached to NICE’s final draft guidance recommending Lucentis as an option for patients …
NICE ‘yes’ for Jetrea
October 23, 2013Sales and Marketing Jetrea, NHS, NICE, eye
Jetrea has completed its seemingly inexorable journey to NHS use in England and Wales for a rare eye condition following …
Eisai: reform NICE or we’ll pull out of the UK
October 21, 2013Research and Development, Sales and Marketing Eisai, Hatfield, Hunt, NICE
Eisai has criticised NICE for being too narrow minded on assessing new drugs, and has warned it may pull its …
Astellas gets NICE nod
October 18, 2013Sales and Marketing Cancer, NHS, NICE, Xtandi
Astellas Pharma’s new prostate cancer drug Xtandi which has been shown to shrink and kill cancer cells, has been recommended …
Patients should ‘top up’ NHS costs
October 16, 2013Sales and Marketing Dixon, England, NHS, NICE, top up
A leading doctor believes that NHS patients must produce top up payments for treatments for non-life threatening conditions. Speaking at …
Price cut not enough for Pixuvri
October 15, 2013Sales and Marketing Cell Therapeutics, NICE, pixuvri
NICE is still saying no to Cell Therapeutics’ lymphoma drug Pixuvri, despite the firm offering a discount on the treatment’s …
SMC must be ‘more flexible’ – health minister
October 9, 2013Sales and Marketing CDF, NICE, SMC
The Scottish health secretary Alex Neil has announced a series of fundamental changes to improve access to new medicines in …
New UK drug pricing plans ‘delayed’
October 7, 2013Medical Communications, Sales and Marketing Drug pricing, Hunt, Lansley, NHS, NICE, VBP
NICE U-turn on MabThera
October 3, 2013Sales and Marketing MabThera, NHS, NICE, Roche
NICE is thinking about recommending Roche’s MabThera for a rare autoimmune condition – a move which represents a partial victory …
Cancer survival rates linked to government spending in EU
October 1, 2013Research and Development, Sales and Marketing CDF, Cancer, EU, NICE
The bigger an EU country’s healthcare budget, the greater its cancer patients’ prospects of survival, according to new research released …
Cancer Drugs Fund to run until 2016
September 30, 2013Research and Development, Sales and Marketing CDF, Cameron, NHS, NICE, VBP
England’s Cancer Drugs Fund will run until 2016 and be given a £400 million boost under plans announced by the …
NICE recommends ovarian cancer drug Caelyx
September 27, 2013Sales and Marketing NICE, Yondelis, ovarian cancer
